Vietnam Pharmaceutical Comprehensive Report
VIETNAM PHARMACEUTICAL INDUSTRY
Products of Vietnamese pharmaceutical companies are mostly concentrated in simple dosage forms, Generic form, low value, overlapping and lack of specific special and complex drugs. The rate of new drug research investment of domestic companies only accounts for about 5% of revenue while foreign companies are 15%.
The total value of the pharmaceutical industry in 2018 is estimated at US $ 5.9 million, of which the major contribution from this growth is from imported pharmaceuticals. Although drug spending per capita increased sharply, reaching USD 61.8 / person / year.
In the first 9 months of 2019, Vietnam's pharmaceutical import turnover increased over the same period in 2018. Pharmaceutical exports increased over the same period in 2018, in which, the main form of payment was TTR accounting for 93%. . Conditions of delivery CIF accounts for about 70%, FOB 8.6% of total export orders.
According to information about declared drug prices published on the website of the Drug Administration of Vietnam - the Ministry of Health, from the beginning of the year to April 19, 2019: Regarding imported medicines, there are 551 times of medicine items declared prices. , 68 times of goods re-declared prices; Regarding domestically produced drugs, there were 1,284 items of price declaration, 173 times of goods subject to re-declaration.
Pharmaceutical products are in the essential demand group, so the economic growth has almost no effect on the growth rate of the industry, the motivation for development of the industry is to be protected from state policies. The trend of M&A between domestic and foreign enterprises is strong for both manufacturing and distribution groups. Vietnam Pharmaceutical Industry is forecast to continue double-digit growth.
Products of Vietnamese pharmaceutical companies are mostly concentrated in simple dosage forms, Generic form, low value, overlapping and lack of specific special and complex drugs. The rate of new drug research investment of domestic companies only accounts for about 5% of revenue while foreign companies are 15%.
The total value of the pharmaceutical industry in 2018 is estimated at US $ 5.9 million, of which the major contribution from this growth is from imported pharmaceuticals. Although drug spending per capita increased sharply, reaching USD 61.8 / person / year.
In the first 9 months of 2019, Vietnam's pharmaceutical import turnover increased over the same period in 2018. Pharmaceutical exports increased over the same period in 2018, in which, the main form of payment was TTR accounting for 93%. . Conditions of delivery CIF accounts for about 70%, FOB 8.6% of total export orders.
According to information about declared drug prices published on the website of the Drug Administration of Vietnam - the Ministry of Health, from the beginning of the year to April 19, 2019: Regarding imported medicines, there are 551 times of medicine items declared prices. , 68 times of goods re-declared prices; Regarding domestically produced drugs, there were 1,284 items of price declaration, 173 times of goods subject to re-declaration.
Pharmaceutical products are in the essential demand group, so the economic growth has almost no effect on the growth rate of the industry, the motivation for development of the industry is to be protected from state policies. The trend of M&A between domestic and foreign enterprises is strong for both manufacturing and distribution groups. Vietnam Pharmaceutical Industry is forecast to continue double-digit growth.
Abbreviations
Report summary
1. BUSINESS ENVIRONMENT
1.1. Macroeconomic situation
1.2. Legal framework
1.3. Trade Agreements
2. PHARMACEUTICAL INDUSTRY OVERVIEW
2.1. Global Pharmaceutical Industry
2.1.1. Production - Consumption
2.1.2. Export - Import
2.1.3. Production and Consumption Situation in major countries
2.1.4. Large Enterprises in the world
2.2. Vietnam Pharmaceutical Industry Overview
2.2.1. History of Vietnam Pharmaceutical Industry
2.2.2. Industry Position
2.2.3. Industry Scale and Feature
2.2.4. Value Chain of Vietnam Pharmaceutical Industry
2.2.5. Raw materials
2.2.6. Production technology
2.2.7. R&D
2.2.8. Production
2.2.9. Consumption
2.2.10. Export - Import
2.2.11. Price movements
2.2.12. Distribution system
2.3. Risks and challenges
2.4. Industry planning
2.5. Driving forces and forecast
3. ENTERPRISE ANALYSIS
3.1. Profitability Ratios
3.2. Cost structure
3.3. Asset Management Ratios
3.4. Capital Structure
3.5. Solvency
3.6. Return on Investment
4. APPENDIX OF FINANCIAL STATEMENTS
Report summary
1. BUSINESS ENVIRONMENT
1.1. Macroeconomic situation
1.2. Legal framework
1.3. Trade Agreements
2. PHARMACEUTICAL INDUSTRY OVERVIEW
2.1. Global Pharmaceutical Industry
2.1.1. Production - Consumption
2.1.2. Export - Import
2.1.3. Production and Consumption Situation in major countries
2.1.4. Large Enterprises in the world
2.2. Vietnam Pharmaceutical Industry Overview
2.2.1. History of Vietnam Pharmaceutical Industry
2.2.2. Industry Position
2.2.3. Industry Scale and Feature
2.2.4. Value Chain of Vietnam Pharmaceutical Industry
2.2.5. Raw materials
2.2.6. Production technology
2.2.7. R&D
2.2.8. Production
2.2.9. Consumption
2.2.10. Export - Import
2.2.11. Price movements
2.2.12. Distribution system
2.3. Risks and challenges
2.4. Industry planning
2.5. Driving forces and forecast
3. ENTERPRISE ANALYSIS
3.1. Profitability Ratios
3.2. Cost structure
3.3. Asset Management Ratios
3.4. Capital Structure
3.5. Solvency
3.6. Return on Investment
4. APPENDIX OF FINANCIAL STATEMENTS
LIST OF TABLES
Table 1: Top pharmaceutical exporting countries, 2016-2018e
Table 2: Top pharmaceutical importing countries, 2016-2018e
Table 3: General information about the healthcare industry of The U.S, 2017e
Table 4: General information about the healthcare industry of Japan, 2017e
Table 5: General information about the healthcare industry of China, 2016e
Table 6: General information about the healthcare industry of Germany, 2017e
Table 7 General information about the healthcare industry of France, 2017e
Table 8: Origin of machinery and equipment of a number of large pharmaceutical companies
Table 9 Some major machineries in pharmaceutical manufacturing line
Table 10: Statistics of drug production by category, 2013 –3/2019e
Table 11:M&A pharmaceutical production group, 2017 - 2018
Table 12: Vietnam’s top import partners, Q1/2019
Table 13: Top exporting enterprises, Q1/2019
Table 14: Price movements of some major drugs in the market, 3/2018 – 3/2019
Table 15: The difference in the price of some drugs at some drug stores, 2019
Table 16: The number of medical facilities, 2010 - 2017
Table 17: Typical chain of pharmacies, 2018
Table 18:M&A in pharmaceutical distribution group, 2017 - 2018
Table 19: Average cost of R&D to produce new drugs (USD million)
Table 20: Top 10 M&A in the world, 2017
Table 21: Top businesses by Biotechnology technology, 2024
Table 22: 10 typical pharmaceutical enterprises in 2018
Table 1: Top pharmaceutical exporting countries, 2016-2018e
Table 2: Top pharmaceutical importing countries, 2016-2018e
Table 3: General information about the healthcare industry of The U.S, 2017e
Table 4: General information about the healthcare industry of Japan, 2017e
Table 5: General information about the healthcare industry of China, 2016e
Table 6: General information about the healthcare industry of Germany, 2017e
Table 7 General information about the healthcare industry of France, 2017e
Table 8: Origin of machinery and equipment of a number of large pharmaceutical companies
Table 9 Some major machineries in pharmaceutical manufacturing line
Table 10: Statistics of drug production by category, 2013 –3/2019e
Table 11:M&A pharmaceutical production group, 2017 - 2018
Table 12: Vietnam’s top import partners, Q1/2019
Table 13: Top exporting enterprises, Q1/2019
Table 14: Price movements of some major drugs in the market, 3/2018 – 3/2019
Table 15: The difference in the price of some drugs at some drug stores, 2019
Table 16: The number of medical facilities, 2010 - 2017
Table 17: Typical chain of pharmacies, 2018
Table 18:M&A in pharmaceutical distribution group, 2017 - 2018
Table 19: Average cost of R&D to produce new drugs (USD million)
Table 20: Top 10 M&A in the world, 2017
Table 21: Top businesses by Biotechnology technology, 2024
Table 22: 10 typical pharmaceutical enterprises in 2018
LIST OF FIGURES
Figure 1: GDP growth rate by quarter (%), 2016 - 2019
Figure 2: Consumer drug and medical service price index, 2012 - Q1/2019
Figure 3: VND/USD exchange rate, 1/2013 - 3/2019
Figure 4: VND/CNY exchange rate, 1/2016 – 3/2019
Figure 5: Population structure, 1999 - 2018
Figure 6: Population and population growth, 2006 -2018
Figure 7: Import of pharmaceuticals, 2012 - Q1/2019
Figure 8: The number of new drugs authorized by the FDA, 2010 - 2018
Figure 9: Investment in R&D in the world, 2010 - 2024f
Figure 10: Top 10 enterprises with the largest R & D costs, 2017
Figure 11: Top 10 enterprises with the largest R & D costs, 2024
Figure 12: Revenue of the global pharmaceutical industry, 2010 - 2017e
Figure 13: Worldwide prescription drug sales, 2010 - 2017
Figure 14: Worldwide Drug Sales by Technology, 2010 - 2017
Figure 15: Drug consumption by types, 2011 - 2017
Figure 16: Drug consumption by group, 2017
Figure 17: Top 10 therapeutic classes by estimated global pharmaceutical sales*, 2017
Figure 18: Worldwide pharmaceutical exports, 2010 - 2018e
Figure 19: Revenue of China’s pharmaceutical industry, 2012 - 2016
Figure 20: Top 10 pharmaceutical enterprises with largest revenue, 2018
Figure 21: Import of raw materials, 2012 - Q1/2019
Figure 22: Import of pharmaceutical raw materials, Q1/2018 - Q1/2019e
Figure 23: Average capital, fixed assets and long-term average investment of enterprises, 2010 - 2017
Figure 24: Number of enterprises and workers in medicine, chemical and pharmaceutical manufacturing sectors, 2010 - 2017
Figure 25: Revenue and profit before tax, 2010 - 2017
Figure 26: Domestic pharmaceutical production value, 2010 - 2018e
Figure 27: Market value of pharmaceutical industry, 2010 - 2018e
Figure 28: Value ratio of domestically produced medicines in Vietnam, 2010 – 2018e
Figure 29: Domestically produced medicine consumption, 2010 – 3/2019e
Figure 30: Spending on medicines in Vietnam, 2009 – 2017e
Figure 31: Spending on medicines per capita in some countries, 2017e
Figure 32: Medicines consumption structure by channel, 2011- 2018e
Figure 33: Current status of Patented and Generic drugs, 2011 - 2018e
Figure 34: Market value of prescription drugs (ETC), 2011 – 2017e
Figure 35: Market value of non-prescription drugs (OTC), 2010 – 2017e
Figure 36: OTC revenue structure by selling channel, 2018
Figure 37: Patened drugs (Patent), 2010 – 2018e
Figure 38: Generic drug market, 2010 – 2018e
Figure 39: Import of pharmaceuticals, 2012 - Q1/2019e
Figure 40: Pharmaceutical imports, 2017 – Q1/2019e
Figure 41: Pharmaceuticals imports from India, 2013 – Q1/2019
Figure 42: Top importing enterprises *, Q1/2019
Figure 43: Pharmaceutical export, 2012 - Q1/2019
Figure 44: Export structure by country, Q1/2019
Figure 45: Rate of drug re-price (increase), 2013 - 2018
Figure 46: Top pharmaceuticals distribution enterprise by revenue, 2018e
Figure 47: Typical drug distribution chains, 2017-2018
Figure 48: Unqualified sample ratio, 2010 – 2016e
Figure 49: Total healthcare expenses, 2010 – 2017f
Figure 50: Population tower, 2018
Figure 51: Over-60 population growth in the world, 1950 – 2050
Figure 52: M&A of pharmaceutical industry, 2010 - 9T/2018
Figure 53: Sales of prescription drugs, 2017 - 2024f
Figure 54: Sales of top largest companies, 2024f
Figure 55: Production of drugs according to technology, 2017 - 2024f
Figure 56: Growth of total drug consumption value in Vietnam, 2012 - 2022f
Figure 57: Drug expenditure per capita, 2017 - 2022f
Figure 58: DHG’s Shareholder structure, 2018
Figure 59: TRA ‘s Shareholder structure, 2018
Figure 60: DMC ‘s Shareholder structure, 2018
Figure 61: Imexpharm ‘s Shareholder structure, 2018
Figure 62: OPC ‘s Shareholder structure, 2018
Figure 63: SPM ‘s Shareholder structure, 2018
Figure 64: Vimedimex ‘s Shareholder structure, 2018
Figure 65: DHT ‘s Shareholder structure, 2018
Figure 66: DBT ‘s Shareholder structure, 2018
Figure 67: LDP ‘s Shareholder structure, 2018
Figure 68: Gross profit margin, 2017 - 2018
Figure 69: Selling expenses, 2017 - 2018
Figure 70: Enterprise management costs, 2017 - 2018
Figure 71: Inventory days, 2018
Figure 72: Average collection period, 2018
Figure 73: Asset rotation, 2018
Figure 74: Self-financing ratio, 2017 - 2018
Figure 75: Solvency, 2017 - 2018
Figure 76: Profit ratio, 2017 - 2018
Figure 1: GDP growth rate by quarter (%), 2016 - 2019
Figure 2: Consumer drug and medical service price index, 2012 - Q1/2019
Figure 3: VND/USD exchange rate, 1/2013 - 3/2019
Figure 4: VND/CNY exchange rate, 1/2016 – 3/2019
Figure 5: Population structure, 1999 - 2018
Figure 6: Population and population growth, 2006 -2018
Figure 7: Import of pharmaceuticals, 2012 - Q1/2019
Figure 8: The number of new drugs authorized by the FDA, 2010 - 2018
Figure 9: Investment in R&D in the world, 2010 - 2024f
Figure 10: Top 10 enterprises with the largest R & D costs, 2017
Figure 11: Top 10 enterprises with the largest R & D costs, 2024
Figure 12: Revenue of the global pharmaceutical industry, 2010 - 2017e
Figure 13: Worldwide prescription drug sales, 2010 - 2017
Figure 14: Worldwide Drug Sales by Technology, 2010 - 2017
Figure 15: Drug consumption by types, 2011 - 2017
Figure 16: Drug consumption by group, 2017
Figure 17: Top 10 therapeutic classes by estimated global pharmaceutical sales*, 2017
Figure 18: Worldwide pharmaceutical exports, 2010 - 2018e
Figure 19: Revenue of China’s pharmaceutical industry, 2012 - 2016
Figure 20: Top 10 pharmaceutical enterprises with largest revenue, 2018
Figure 21: Import of raw materials, 2012 - Q1/2019
Figure 22: Import of pharmaceutical raw materials, Q1/2018 - Q1/2019e
Figure 23: Average capital, fixed assets and long-term average investment of enterprises, 2010 - 2017
Figure 24: Number of enterprises and workers in medicine, chemical and pharmaceutical manufacturing sectors, 2010 - 2017
Figure 25: Revenue and profit before tax, 2010 - 2017
Figure 26: Domestic pharmaceutical production value, 2010 - 2018e
Figure 27: Market value of pharmaceutical industry, 2010 - 2018e
Figure 28: Value ratio of domestically produced medicines in Vietnam, 2010 – 2018e
Figure 29: Domestically produced medicine consumption, 2010 – 3/2019e
Figure 30: Spending on medicines in Vietnam, 2009 – 2017e
Figure 31: Spending on medicines per capita in some countries, 2017e
Figure 32: Medicines consumption structure by channel, 2011- 2018e
Figure 33: Current status of Patented and Generic drugs, 2011 - 2018e
Figure 34: Market value of prescription drugs (ETC), 2011 – 2017e
Figure 35: Market value of non-prescription drugs (OTC), 2010 – 2017e
Figure 36: OTC revenue structure by selling channel, 2018
Figure 37: Patened drugs (Patent), 2010 – 2018e
Figure 38: Generic drug market, 2010 – 2018e
Figure 39: Import of pharmaceuticals, 2012 - Q1/2019e
Figure 40: Pharmaceutical imports, 2017 – Q1/2019e
Figure 41: Pharmaceuticals imports from India, 2013 – Q1/2019
Figure 42: Top importing enterprises *, Q1/2019
Figure 43: Pharmaceutical export, 2012 - Q1/2019
Figure 44: Export structure by country, Q1/2019
Figure 45: Rate of drug re-price (increase), 2013 - 2018
Figure 46: Top pharmaceuticals distribution enterprise by revenue, 2018e
Figure 47: Typical drug distribution chains, 2017-2018
Figure 48: Unqualified sample ratio, 2010 – 2016e
Figure 49: Total healthcare expenses, 2010 – 2017f
Figure 50: Population tower, 2018
Figure 51: Over-60 population growth in the world, 1950 – 2050
Figure 52: M&A of pharmaceutical industry, 2010 - 9T/2018
Figure 53: Sales of prescription drugs, 2017 - 2024f
Figure 54: Sales of top largest companies, 2024f
Figure 55: Production of drugs according to technology, 2017 - 2024f
Figure 56: Growth of total drug consumption value in Vietnam, 2012 - 2022f
Figure 57: Drug expenditure per capita, 2017 - 2022f
Figure 58: DHG’s Shareholder structure, 2018
Figure 59: TRA ‘s Shareholder structure, 2018
Figure 60: DMC ‘s Shareholder structure, 2018
Figure 61: Imexpharm ‘s Shareholder structure, 2018
Figure 62: OPC ‘s Shareholder structure, 2018
Figure 63: SPM ‘s Shareholder structure, 2018
Figure 64: Vimedimex ‘s Shareholder structure, 2018
Figure 65: DHT ‘s Shareholder structure, 2018
Figure 66: DBT ‘s Shareholder structure, 2018
Figure 67: LDP ‘s Shareholder structure, 2018
Figure 68: Gross profit margin, 2017 - 2018
Figure 69: Selling expenses, 2017 - 2018
Figure 70: Enterprise management costs, 2017 - 2018
Figure 71: Inventory days, 2018
Figure 72: Average collection period, 2018
Figure 73: Asset rotation, 2018
Figure 74: Self-financing ratio, 2017 - 2018
Figure 75: Solvency, 2017 - 2018
Figure 76: Profit ratio, 2017 - 2018
